[go: up one dir, main page]

WO2001022952A3 - Use of tace inhibitors - Google Patents

Use of tace inhibitors Download PDF

Info

Publication number
WO2001022952A3
WO2001022952A3 PCT/EP2000/009218 EP0009218W WO0122952A3 WO 2001022952 A3 WO2001022952 A3 WO 2001022952A3 EP 0009218 W EP0009218 W EP 0009218W WO 0122952 A3 WO0122952 A3 WO 0122952A3
Authority
WO
WIPO (PCT)
Prior art keywords
tace inhibitors
tace
inhibitors
atopic
allergy
Prior art date
Application number
PCT/EP2000/009218
Other languages
French (fr)
Other versions
WO2001022952A2 (en
Inventor
Andrew Faller
Ruth Judik Mayer
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Andrew Faller
Ruth Judik Mayer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp, Andrew Faller, Ruth Judik Mayer filed Critical Smithkline Beecham Plc
Priority to AU74208/00A priority Critical patent/AU7420800A/en
Publication of WO2001022952A2 publication Critical patent/WO2001022952A2/en
Publication of WO2001022952A3 publication Critical patent/WO2001022952A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Inhibitors of tumor necrosis factor alpha converting enzyme (TACE) are useful in the treatment or prophylaxis of allergy, allergic asthma, atopic dermatitis and other atopic diseases.
PCT/EP2000/009218 1999-09-25 2000-09-21 Use of tace inhibitors WO2001022952A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU74208/00A AU7420800A (en) 1999-09-25 2000-09-21 Medical use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922825.6A GB9922825D0 (en) 1999-09-25 1999-09-25 Medical use
GB9922825.6 1999-09-25

Publications (2)

Publication Number Publication Date
WO2001022952A2 WO2001022952A2 (en) 2001-04-05
WO2001022952A3 true WO2001022952A3 (en) 2003-02-20

Family

ID=10861673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009218 WO2001022952A2 (en) 1999-09-25 2000-09-21 Use of tace inhibitors

Country Status (3)

Country Link
AU (1) AU7420800A (en)
GB (1) GB9922825D0 (en)
WO (1) WO2001022952A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
AU2006265694B2 (en) * 2005-07-05 2010-03-18 Seacarb Pty Ltd Preparation and use of cationic halides, sequestration of carbon dioxide
JP2022512584A (en) 2018-10-04 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル EGFR inhibitor for treating keratoderma

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
WO1995006031A1 (en) * 1993-08-23 1995-03-02 Immunex Corporation Inhibitors of tnf-alpha secretion
US5629285A (en) * 1993-08-23 1997-05-13 Immunex Corporation Inhibitors of TNF-α secretion
WO1997022587A1 (en) * 1995-12-15 1997-06-26 Novartis Ag Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors
WO1997024117A1 (en) * 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
WO1997026257A1 (en) * 1996-01-17 1997-07-24 Smithkline Beecham Plc Hydroxamic acid based collagenase inhibitors
WO1997043249A1 (en) * 1996-05-10 1997-11-20 Smithkline Beecham Plc INHIBITORS OF THE PRODUCTION OF s-CD23 AND THE SECRETION OF TNF
WO1998005635A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO1998030551A1 (en) * 1997-01-07 1998-07-16 Abbott Laboratories MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNFα SECRETION
WO1998042659A2 (en) * 1997-03-26 1998-10-01 Smithkline Beecham Plc Aryl- or heteroarylsulfonamide substituted hydroxamic acid derivates, process for their preparation and their use as pharmaceuticals
WO1998043959A1 (en) * 1997-03-28 1998-10-08 Zeneca Limited Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor
WO2000009492A1 (en) * 1998-08-12 2000-02-24 Pfizer Products Inc. Tace inhibitors
WO2000069812A1 (en) * 1999-05-17 2000-11-23 Daiichi Fine Chemical Co., Ltd. Novel hydroxamic acid derivatives

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
WO1995006031A1 (en) * 1993-08-23 1995-03-02 Immunex Corporation Inhibitors of tnf-alpha secretion
US5629285A (en) * 1993-08-23 1997-05-13 Immunex Corporation Inhibitors of TNF-α secretion
WO1997022587A1 (en) * 1995-12-15 1997-06-26 Novartis Ag Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors
WO1997024117A1 (en) * 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
WO1997026257A1 (en) * 1996-01-17 1997-07-24 Smithkline Beecham Plc Hydroxamic acid based collagenase inhibitors
WO1997043249A1 (en) * 1996-05-10 1997-11-20 Smithkline Beecham Plc INHIBITORS OF THE PRODUCTION OF s-CD23 AND THE SECRETION OF TNF
WO1998005635A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO1998030551A1 (en) * 1997-01-07 1998-07-16 Abbott Laboratories MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNFα SECRETION
WO1998042659A2 (en) * 1997-03-26 1998-10-01 Smithkline Beecham Plc Aryl- or heteroarylsulfonamide substituted hydroxamic acid derivates, process for their preparation and their use as pharmaceuticals
WO1998043959A1 (en) * 1997-03-28 1998-10-08 Zeneca Limited Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor
WO2000009492A1 (en) * 1998-08-12 2000-02-24 Pfizer Products Inc. Tace inhibitors
WO2000069812A1 (en) * 1999-05-17 2000-11-23 Daiichi Fine Chemical Co., Ltd. Novel hydroxamic acid derivatives

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199731, Derwent World Patents Index; Class B05, AN 1997-341618, XP002186118 *
DATABASE WPI Section Ch Week 199734, Derwent World Patents Index; Class B03, AN 1997-372446, XP002186119 *
DATABASE WPI Section Ch Week 199816, Derwent World Patents Index; Class B05, AN 1998-178991, XP002186120 *
DATABASE WPI Section Ch Week 199836, Derwent World Patents Index; Class B03, AN 1998-427535, XP002186121 *
DATABASE WPI Section Ch Week 199846, Derwent World Patents Index; Class B02, AN 1998-542611, XP002186122 *
DATABASE WPI Section Ch Week 200106, Derwent World Patents Index; Class B05, AN 2001-049806, XP002186117 *
FODA HUSSEIN D ET AL: "Regulation of gelatinases in human airway smooth muscle cells: Mechanism of progelatinase A activation.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 277, no. 1 PART 1, July 1999 (1999-07-01), pages L174 - L182, XP001050509, ISSN: 0002-9513 *
LIEDTKE W ET AL: "A matrix metalloprotease inhibitor is effective in acute and chronic recurrent experimental allergic encephalomyelitis (EAE).", EUROPEAN CYTOKINE NETWORK, vol. 7, no. 2, 1996, 6th International Tumor Necrosis Factor Congress;Rhodes, Greece; May 8-12, 1996, pages 284, XP001050544, ISSN: 1148-5493 *

Also Published As

Publication number Publication date
AU7420800A (en) 2001-04-30
GB9922825D0 (en) 1999-11-24
WO2001022952A2 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
AU2003206311A1 (en) Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2002020002A3 (en) A method for treating allergies
WO2003088897A3 (en) Fab i inhibitors
WO2000051587A3 (en) Jak-3 inhibitors for treating allergic disorders
AU2002350289A1 (en) Polysaccharide biomaterials and methods of use thereof
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
AU2002367979A1 (en) Devices, systems and methods for reducing levels of pro-inflammartory or anti-inflammatrory stimulators or mediators in blood products
AU2386201A (en) Substituted sapogenins and their use
WO2003084560A3 (en) Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
AU2002351248A1 (en) Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in physiologic fluids
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
AU2002344447A1 (en) Bacterium of the genus bifidobacterium and fermented foods using the same
AU2002363411A1 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
AU2002363973A1 (en) Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
WO2004032850A3 (en) Uses of human zven antagonists
AU2003229258A1 (en) Allergy vaccine composition, production method thereof and use of same in allergy treatment
WO2001022952A3 (en) Use of tace inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP